title: [Correlation of DNA ploidy, c-erbB-2 protein tissue status, level of PCNA expression and clinical outcome in gastric carcinomas].
abstract: One-hundred and sixty-four patients with gastric carcinomas, who underwent gastrectomy during 1979-1985, were studied. Sixty-five of these cases were early gastric carcinomas, and the others were advanced gastric carcinomas, and the others were advanced gastric carcinomas. The nuclear DNA contents were measured by cytofluorometry, and immunohistochemical study on the expression of c-erbB-2 protein was performed using a monoclonal antibody against the c-erbB-2 oncogene product. Furthermore, immunohistochemical detection of proliferating cell nuclear antigen (PCNA) was performed using a monoclonal antibody against the PCNA. The rates of positive invasion beyond submucosal layer, lymphatic invasion, and vascular invasion in aneuploid cases were significantly higher than those in diploid ones, and the patients with aneuploid tumor had a significantly worse prognosis than those with diploid tumor. The rates of positive lymph node metastases and invasion beyond submucosal layer in the group with positive staining of the c-erbB-2 protein was significantly higher than in the negative group, and the group with positive staining for c-erbB-2 had a significantly worse prognosis than the negative one. PCNA indices showed a significant correlation with lymph node metastasis, and the group with higher PCNA indices had a worse prognosis. The patients with tumor showing both aneuploid and positive staining for c-erbB-2 protein, had the worst prognosis. There is a relationship between c-erbB-2 tissue status and PCNA indices, but no correlations were found among c-erbB-2 tissue status, PCNA indices and DNA contents. From these results, it can be concluded that DNA ploidy, c-erbB-2 protein, and PCNA may reflect the malignant potential of gastric carcinoma.
authors.affiliation: Dept. of Surgery II, School of Medicine, Kanazawa University.
authors.forename: H
authors.initials: H
authors.lastname: Takamura
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: Y
authors.initials: Y
authors.lastname: Hirono
authors.forename: I
authors.initials: I
authors.lastname: Ninomiya
authors.forename: H
authors.initials: H
authors.lastname: Sahara
authors.forename: K
authors.initials: K
authors.lastname: Tsugawa
authors.forename: H
authors.initials: H
authors.lastname: Matsumoto
authors.forename: K
authors.initials: K
authors.lastname: Sugiyama
authors.forename: T
authors.initials: T
authors.lastname: Fujimura
authors.forename: G
authors.initials: G
authors.lastname: Nishimura
mesh_terms: D000911:Antibodies, Monoclonal; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics*; D006801:Humans; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D009687:Nuclear Proteins / Q000032:analysis*; D011003:Ploidies; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases; D012044:Regression Analysis; D013274:Stomach Neoplasms / Q000235:genetics* / Q000276:immunology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D004273:DNA, Neoplasm; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases